financetom
Business
financetom
/
Business
/
--Concentrix Guides For Q4 EPS of $2.90-$3.16 on Revenue of $2.42-$2.47 Billion, vs CIQ Analyst Consensus of $3.48/Share on Revenue of $2.46 Billion
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
--Concentrix Guides For Q4 EPS of $2.90-$3.16 on Revenue of $2.42-$2.47 Billion, vs CIQ Analyst Consensus of $3.48/Share on Revenue of $2.46 Billion
Oct 3, 2024 1:32 AM

04:08 PM EDT, 09/25/2024 (MT Newswires) --

Price: 58.50, Change: -5.12, Percent Change: -8.05

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
JPMorgan unit backs Centivo's $75 million equity and debt raise
JPMorgan unit backs Centivo's $75 million equity and debt raise
Sep 24, 2024
(Reuters) - Healthcare firm Centivo on Tuesday said it has secured $75 million in equity and debt financing, backed by Cone Health Ventures and the largest U.S. bank JPMorgan Chase's division Morgan Health. The company did not disclose the valuation at which the latest capital was raised. Centivo offers a primary care-centered health plan as an alternative to traditional U.S....
Sangoma Technologies Fiscal Q4 Loss Narrows, Revenue Slips; Shares Rise After Hours
Sangoma Technologies Fiscal Q4 Loss Narrows, Revenue Slips; Shares Rise After Hours
Sep 24, 2024
05:30 PM EDT, 09/18/2024 (MT Newswires) -- Sangoma Technologies ( SANG ) reported a fiscal Q4 net loss late Wednesday of $0.05 per diluted share, compared with a $0.72 net loss a year earlier. Four analysts polled by Capital IQ expected a loss of $0.03. Revenue for the quarter that ended June 30 was $60.9 million, down from $63.7 million...
Eli Lilly's Alzheimer's drug approved in Japan
Eli Lilly's Alzheimer's drug approved in Japan
Sep 24, 2024
(Reuters) - Eli Lilly ( LLY ) said on Tuesday Japan's health ministry has approved donanemab, its drug for Alzheimer's disease, providing patients with another treatment option after Eisai ( ESALF ) and Biogen's Leqembi received the nod in September last year. Lilly said Japan is the second major market in which the drug has received approval, after the United...
Caci International Insider Sold Shares Worth $4,924,115, According to a Recent SEC Filing
Caci International Insider Sold Shares Worth $4,924,115, According to a Recent SEC Filing
Sep 24, 2024
05:21 PM EDT, 09/18/2024 (MT Newswires) -- Gregory R Bradford, Chief Executive, CACI Limited, on September 16, 2024, sold 10,000 shares in Caci International ( CACI ) for $4,924,115. Following the Form 4 filing with the SEC, Bradford has control over a total of 35,538 shares of the company, with 35,538 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/16058/000001605824000149/xslF345X05/wk-form4_1726693874.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved